挽救新冠患者 美国 FDA 允许使用实验性方案：血浆疗法

近日，美国食药监局 FDA 更新了新冠治疗的实验性方案，增加了血浆疗法。

血浆疗法是指从已治愈的新冠患者身上抽取血浆，并将其输到患者体内的治疗方法，因为已治愈患者体内已经产生了新冠病毒抗体，短期内不会再感染新冠病毒，将这种血浆输入患者体内后，也可能会帮助患者产生同样的抗体来抵抗病毒。

不过该疗法未经过临床验证，FDA 仅批准在患者生命遭到严重威胁时的紧急情况下才可使用血浆疗法。

国内多家医院和研究团队早在 2 月份就已采用这种疗法，并取得了相当不错的治疗效果，其中由国药中国生物采取的新冠状肺炎康复者血浆治疗研究团队在武汉治疗近 50 名重症患者，已有 6 位患者出院，大部分患者都有好转，近期也将陆续出院。

有数据显示，捐献一次血浆可以挽救 2-3 名新冠患者。

此外也有研究显示正常人输入血浆后也能起到一定的预防效果，不过 FDA 明确禁止将其用于任何预防用途。
Recently, FDA of US Food and Drug Administration updated the experimental plan of new crown therapy and added plasma therapy. Plasma therapy refers to the treatment method of extracting plasma from the cured patients with new coronavirus and transferring it to the patients, because the cured patients have already produced antibodies to the new coronavirus and will not be infected with the new coronavirus in a short period of time. After the plasma is transferred to the patients, it may also help the patients produce the same antibodies to resist the virus. However, the therapy has not been clinically verified, and FDA only approves the use of plasma therapy in emergency situations when the patient’s life is seriously threatened. Many hospitals and research teams in China have already adopted this therapy as early as February and have achieved quite good therapeutic effects. Among them, the plasma therapy research team for patients recovering from new coronal pneumonia, which is adopted by Chinese medicine Chinese Biology, has treated nearly 50 severe patients in Wuhan, and 6 patients have been discharged from hospital. Most patients have improved and will be discharged in succession in the near future. Data show that a donation of plasma can save 2-3 newly crowned patients. In addition, some studies have shown that normal people can also have certain preventive effects after blood plasma infusion, but FDA explicitly prohibits its use for any preventive purpose.